ClinicalTrials.gg
RecruitingNCT06686355YQSIMDUpdated Mar 30, 2026

The Treatment of Sepsis Induced Myocardial Dysfunction With Yiqilishui Formula

A Phase 2 interventional study of Yiqilishui formula and Placebo in Sepsis Induced Myocardial Dysfunction, sponsored by Dongzhimen Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Dongzhimen Hospital, Beijing · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 286 studies in Sepsis with a site in China — 99 open to participants now, 106 under way, 5 of them phase 3. Sepsis · China.

Planned enrollment
70th of 121
80 · median 118
Started
2024
with 25 others
Phase 2
12 of 286
4 open now
Primary completion
2026-12
later than 50 of 105 live
Registered
215th of 286
by date

Among the 286 studies in Sepsis with a site in China, this one is the 70th largest by planned enrollment of the 121 interventional ones that give a count, is one of 26 that started in 2024, is one of 12 in phase 2, reaches primary completion later than 50 of the 105 other live ones, and was the 215th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

99 of the 286 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 286 studies in Sepsis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if Chinese medicine - Yiqilishui formula works to treat sepsis-induced myocardial dysfunction (SIMD). It will also learn about the safety of Yiqilishui formula. The main questions it aims to answer are:

  • Compared with conventional western traetment alone, can supplementing conventional Western treatment with Yiqilishui formula better improve the heart function and reduce mortality of participants with SIMD?
  • What medical problems do participants have when taking Yiqilishui formula? Researchers will compare Yiqilishui formula to a placebo (a look-alike substance that contains no drug) to see if Yiqilishui formula works to treat SIMD.

Participants will:

  • Take Yiqilishui formula granules or placebo twice daily for 7 days, while receiving standard conventional Western treatment.
  • Undergo blood drawing, electrocardiogram and transthoracic echocardiography at enrollment, on the 3rd day, the 7th day, and the 14th day after enrollment.
Read the detailed description

Sepsis-induced myocardial dysfunction (SIMD) is characterized by high morbidity and mortality rates and remains a challenging issue in the field of critical care that has not yet been resolved. The main pathogenesis involves deficiency of Qi with water overflow and blood stasis and toxin blocking the channels. The use of a Qi-invigorating and diuretic formula has the effect of invigorating Qi, promoting diuresis, and detoxifying and unblocking the channels. This study employed a two-center prospective parallel randomized double-blind controlled trial, selecting a total of 80 SIMD subjects from the ICU of Tongzhou District Traditional Chinese Medicine Hospital and the ICU of Dongzhimen Hospital of Beijing University of Chinese Medicine, who met the inclusion and exclusion criteria. The subjects were randomly and evenly divided into a treatment group and a control group. Both groups received basic SIMD treatment, with the treatment group additionally receiving the oral or nasogastric administration of a granule preparation of Yiqilishui formula, and the control group receiving a placebo orally or nasogastrically. The intervention period was 7 days, with a follow-up period of 28 days. The primary efficacy indicators compared between the two groups were BNP and NT-proBNP, and the secondary efficacy indicators were echocardiography, myocardial injury markers, inflammatory markers, critical illness severity scores, ICU length of stay and costs, and 28-day survival rate. The study aimed to evaluate the clinical efficacy and safety of the Yiqilishui formula for SIMD.

03

Conditions studied

  • Sepsis Induced Myocardial Dysfunction

Browse trials for

Keywords

  • sepsis
  • myocardial dysfunction
  • SIMD
  • Yiqilishui formula
  • Double-blind randomized
  • clinical study
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients hospitalized in the ICU of Tongzhou Traditional Chinese Medicine Hospital and Dongzhimen Hospital of Beijing University of Chinese Medicine between January 2024 and December 2026.
  2. Patients diagnosed with SIMD and qi deficiency and water flooding syndrome.
  3. Aged 50 to 85 years.
  4. SOFA score: 2 to 12 points.
  5. Diagnosis of SIMD within 24 hours.
  6. Signed by the patient or their family.

Exclusion criteria

Exclusion Criteria

  1. Subjects diagnosed with acute coronary syndrome.
  2. Subjects with heart failure caused by cardiomyopathies such as hypertrophic cardiomyopathy, dilated cardiomyopathy, myocardial amyloidosis, diabetic cardiomyopathy, or hypothyroid cardiomyopathy.
  3. Subjects with heart failure caused by structural heart abnormalities, arrhythmias, pulmonary heart disease, or cardiorenal syndrome.
  4. Subjects with severe primary diseases affecting survival, including uncontrolled, unresectable malignant tumors, hematologic diseases, and .
  5. Subjects with liver or kidney dysfunction, with an individual SOFA score of ≥3 for liver or kidney function.
  6. Subjects who have used continuously in the last 6 months or have undergone organ transplantation.
  7. Subjects who have used (equivalent to methylprednisolone ≥20mg/day) continuously within 7 days prior to enrollment.
  8. Subjects who have used Chinese herbal medicines or Chinese patent medicine replenishing qi, activating blood circulation and facilitating diuresis within 14 days prior to enrollment.
  9. Subjects deemed unable to take decoctions by clinicians.
  10. Pregnant or breastfeeding women.
  11. Subjects who have participated in other clinical trials within the last 30 days.
  12. Subjects deemed unable to complete or unsuitable for this study by the researchers (e.g., expected death within 48 hours or refusal of active treatment).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Yiqilishui group

    Conventional Western medicine treatment + oral or nasogastric administration of Yiqilishui formula granules, twice daily;

    Drug: Yiqilishui formula

  • Sham comparator
    placebo group

    Conventional Western medicine treatment + oral or nasal feeding of Yiqilishui formula placebo , twice daily.

    Other: Placebo

Interventions

  • DrugYiqilishui formula

    Astragalus Root 30g, Angelica sinensis 30g, Honeysuckle Flower 30g, Capillary Artemisia Herb 15g, Giant Knotweed Rhizome 15g, Lepidium Seed 30g, Sichuan Lovage Rhizome 15g, Salvia Root 15g, Jujube Fruit 15g;

  • OtherPlacebo

    5% Yiqilishui Granules + 95% Dextrin;

06

What researchers measure

Primary outcomes

  1. BNP(B-type natriuretic peptide) decline rate

    Blood samples were taken from the median cubital vein of the subjects at enrollment, on the 3rd day, the 7th day, and the 14th day to measure the BNP levels in the subjects' venous blood, calculate the patient's BNP decline rate, assess the severity of heart failure in the subjects, and predict their prognosis.

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

Secondary outcomes

  1. The levels of cTnI

    Cardiac injury markers-Blood samples from the median cubital vein of the subjects were taken at enrollment, on the 3rd day, the 7th day, and the 14th day to detect the levels of cardiac troponin I (cTnI)

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  2. The levels of CK-MB

    Cardiac injury markers-Blood samples from the median cubital vein of the subjects were taken at enrollment, on the 3rd day, the 7th day, and the 14th day to detect the levels of creatine kinase MB isoenzyme

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  3. Concentration of H-FABP

    Cardiac injury markers-Blood samples from the median cubital vein of the subjects were taken at enrollment, on the 3rd day, the 7th day, and the 14th day to detect the levels of heart-type fatty acid-binding protein

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  4. Tei index

    At the time of subject enrollment, on the 3rd day, 7th day, and 14th day, Tei index were measured using transthoracic echocardiography to evaluate the subjects' cardiac function and structure.

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  5. MEE

    At the time of subject enrollment, on the 3rd day, 7th day, and 14th day, myocardial energy expenditure

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  6. LVMI

    At the time of subject enrollment, on the 3rd day, 7th day, and 14th day, left ventricular mass index (LVMI) were measured using transthoracic echocardiography to evaluate the subjects' cardiac function and structure.

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  7. The levels of WBC

    Blood is drawn from the median cubital vein of the subjects at enrollment, on the 3rd day, the 7th day, and the 14th day. The levels of white blood cells (WBC) in the subjects' venous blood is detected.

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  8. The percentage of NE%

    Blood is drawn from the median cubital vein of the subjects at enrollment, on the 3rd day, the 7th day, and the 14th day. The percentage of neutrophils (NE%) in the subjects' venous blood is detected.

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  9. The levels of CRP

    Blood is drawn from the median cubital vein of the subjects at enrollment, on the 3rd day, the 7th day, and the 14th day. The levels of C-reactive protein (CRP) in the subjects' venous blood is detected.

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  10. The levels of PCT

    Blood is drawn from the median cubital vein of the subjects at enrollment, on the 3rd day, the 7th day, and the 14th day. The levels of procalcitonin (PCT) in the subjects' venous blood is detected.

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  11. Concentration of IL-6

    The supernatant serum is obtained by centrifugation, and the levels of interleukin-6 (IL-6) is measured by ELISA.

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  12. Concentration of TNF-α

    The supernatant serum is obtained by centrifugation, and the levels of tumor necrosis factor-α (TNF-α) is measured by ELISA.

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  13. Concentration of ROS

    The supernatant serum is obtained by centrifugation, and reactive oxygen species (ROS)is measured by ELISA.

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  14. Concentration of ATP

    The supernatant serum is obtained by centrifugation, and the levels of ATP content in the subjects' serum is measured by ELISA.

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  15. Platelet aggregation rate

    At enrollment, D3, D7, and D14, venous blood from patients is collected, platelet-rich plasma is prepared using differential centrifugation, and the platelet aggregation rate is determined by optical turbidimetry.

    Time frame: At enrollment, on the 3rd day, the 7th day, and the 14th day

  16. SOFA score

    Sequential Organ Failure Assessment (SOFA score) is performed at the time of enrollment, on the 7th day, and on the 14th day. The SOFA score includes six systems: respiratory, circulation, liver, coagulation, kidney and central nervous system. Each system is scored according to different variables, with a score of 0 to 4 points, and a total score of 0 to 24 points. The higher the score, the worse the outcome.

    Time frame: At enrollment, the 7th day, and the 14th day

  17. Apache II score

    Acute Physiology and Chronic Health Evaluation (Apache II score) is performed at the time of enrollment, on the 7th day, and on the 14th day. The Apache II score is scored from 0 to 71, and the higher the score, the worse the outcome.

    Time frame: At enrollment, the 7th day, and the 14th day

  18. ICU length of stay;

    ICU length of stay,up to 100 weeks.

    Time frame: From the date the participant is transferred to the ICU to the date he or she is finally transferred out of the ICU, assessed up to 100 weeks.

  19. Outcome indicator

    28-day mortality rate

    Time frame: 28th day

Other outcomes

  1. The level of body temperature

    During the intervention period, record the patient's underarm temperature measurement daily.

    Time frame: Daily from enrollment to the 7th day.

  2. Breathing rate

    During the intervention period, record the patient's breathing rate measurement daily.

    Time frame: Daily from enrollment to the 7th day.

  3. Heart rate

    During the intervention period, record the patient's heart rate measurement daily.

    Time frame: Daily from enrollment to the 7th day.

  4. The levels of blood pressure

    During the intervention period, record the patient's blood pressure measurement daily.

    Time frame: Daily from enrollment to the 7th day.

  5. The levels of ALT

    Before and after intervention period, record the patient's the levels of ALT.

    Time frame: At enrollment and on the 7th day.

  6. The levels of AST

    Before and after intervention period, record the patient's the levels of AST.

    Time frame: At enrollment and on the 7th day.

  7. The levels of BUN

    Before and after intervention period, record the patient's the levels of BUN.

    Time frame: At enrollment and on the 7th day.

  8. The levels of Cr

    Before and after intervention period, record the patient's the levels of Cr.

    Time frame: At enrollment and on the 7th day.

  9. The levels of PT

    Before and after intervention period, record the patient's the levels of Prothrombin Time(PT).

    Time frame: At enrollment and on the 7th day.

  10. The levels of APTT

    Before and after intervention period, record the patient's the levels of Activated Partial Thromboplastin Time(APTT).

    Time frame: At enrollment and on the 7th day.

  11. The levels of INR

    Before and after intervention period, record the patient's the levels of international normalized ratio(INR).

    Time frame: At enrollment and on the 7th day.

  12. The levels of TT

    Before and after intervention period, record the patient's the levels of Thrombin Time(TT).

    Time frame: At enrollment and on the 7th day.

  13. The levels of D-D

    Before and after intervention period, record the patient's the levels of D-dimer(D-D).

    Time frame: At enrollment and on the 7th day.

  14. The levels of FDP

    Before and after intervention period, record the patient's the levels of Fibrin degradation products(FDP).

    Time frame: At enrollment and on the 7th day.

  15. Unexpected adverse reactions

    Unexpected adverse reactions occurred during the intervention period.

    Time frame: From enrollment to the 7th day, unexpected adverse reactions should be recorded at any time during the intervention period.

07

Study locations

1 of 1 sites recruiting
  • Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
    Beijing, 100007, China
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.

Of 43 non-industry phase 2 interventional studies under Sepsis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 35. This study's planned 25 months is below that.

Counting every sponsor, half of 60 studies reached it within 29 months; a quarter within 16 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Nov 13, 2024
StartActual
Nov 20, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06686355
Lead sponsor
Dongzhimen Hospital, Beijing
Responsible party
Xiu Shengyao (Principal Investigator, Dongzhimen Hospital, Beijing) — Principal investigator
First posted
Nov 13, 2024
Start date
Nov 20, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 30, 2026

Study contacts

Guoxia Zhang
Contact
2721064904@qq.com
+86-010-84013192

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion